Johnson & Johnson (JNJ)

Basic

  • Market Cap

    $390.51B

  • EV

    $398.01B

  • Shares Out

    2,408.77M

  • Revenue

    $85.16B

  • Employees

Margins

  • Gross

    69.18%

  • EBITDA

    36.13%

  • Operating

    27.79%

  • Pre-Tax

    17.69%

  • Net

    41.28%

  • FCF

    20.88%

Returns (5Yr Avg)

  • ROA

    7.91%

  • ROTA

    104.78%

  • ROE

    30.37%

  • ROCE

    16.94%

  • ROIC

    15.2%

Valuation (TTM)

  • P/E

  • P/B

  • EV/Sales

  • EV/EBITDA

  • P/FCF

  • EV/Gross Profit

Valuation (NTM)

  • Price Target

    $174.24

  • P/E

  • PEG

  • EV/Sales

  • EV/EBITDA

  • P/FCF

Financial Health

  • Cash

    $22.93B

  • Net Debt

    $7,505M

  • Debt/Equity

    0.44

  • EBIT/Interest

    30.65

Growth (CAGR)

  • Rev 3Yr

    1.03%

  • Rev 5Yr

    0.86%

  • Rev 10Yr

    1.79%

  • Dil EPS 3Yr

    -1.91%

  • Dil EPS 5Yr

    -1.51%

  • Dil EPS 10Yr

    0.79%

  • Rev Fwd 2Yr

    3.2%

  • EBITDA Fwd 2Yr

    4.03%

  • EPS Fwd 2Yr

    5.63%

  • EPS LT Growth Est

    4.32%

Dividends

  • Yield

  • Payout

    89.36%

  • DPS

    $4.7

  • DPS Growth 3Yr

    5.7%

  • DPS Growth 5Yr

    5.83%

  • DPS Growth 10Yr

    6.14%

  • DPS Growth Fwd 2Yr

    4.73%

Select a metric from the list below to chart it

Dec '14

Jan '16

Jan '17

Dec '17

Dec '18

Dec '19

Jan '21

Jan '22

Jan '23

Dec '23

Total Revenues

82,059

82,584

78,740

79,990

85,159

Total Revenues % Chg.

0.6%

0.6%

-4.7%

1.6%

6.5%

Cost of Goods Sold, Total

27,556

28,427

23,402

24,596

26,244

Gross Profit

54,503

54,157

55,338

55,394

58,915

Selling General & Admin Expenses, Total

21,885

21,731

19,506

19,078

20,166

R&D Expenses

11,355

12,159

14,277

14,135

15,085

Other Operating Expenses, Total

33,240

33,890

33,783

33,213

35,251

Operating Income

21,263

20,267

21,555

22,181

23,664

Interest Expense, Total

-318

-201

-183

-276

-772

Interest And Investment Income

357

111

53

490

1,261

Net Interest Expenses

39

-90

-130

214

489

Currency Exchange Gains (Loss)

-267

-209

-216

-286

-366

Other Non Operating Income (Expenses)

-3,909

-2,922

-550

1,744

1,664

EBT, Excl. Unusual Items

17,126

17,046

20,659

23,853

25,451

Restructuring Charges

-266

-247

-209

-275

-798

Merger & Related Restructuring Charges

-300

-200

Gain (Loss) On Sale Of Investments

300

1

-700

-600

Gain (Loss) On Sale Of Assets

2,154

111

617

380

117

Asset Writedown

-1,096

-233

-989

-1,216

-1,295

In Process R&D Expenses

-890

-181

-900

-783

-313

Legal Settlements

-900

-6,900

Other Unusual Items

-700

-400

EBT, Incl. Unusual Items

17,328

16,497

19,178

19,359

15,062

Income Tax Expense

2,209

1,783

1,377

2,989

1,736

Earnings From Continuing Operations

15,119

14,714

17,801

16,370

13,326

Earnings Of Discontinued Operations

3,077

1,571

21,827

Net Income

15,119

14,714

20,878

17,941

35,153

Net Income to Common Incl Extra Items

15,119

14,714

20,878

17,941

35,153

Net Income to Common Excl. Extra Items

15,119

14,714

17,801

16,370

13,326

Total Shares Outstanding

2,632.5

2,632.5

2,629

2,613.6

2,407.1

Weighted Avg. Shares Outstanding

2,645.1

2,632.8

2,632.1

2,625.2

2,533.5

Weighted Avg. Shares Outstanding Dil

2,684.3

2,670.7

2,674

2,663.9

2,560.4

EPS

5.7

5.6

7.9

6.8

13.9

EPS Diluted

5.6

5.5

7.8

6.7

13.7

EBITDA

28,272

27,498

28,206

28,510

30,767